Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

BIOA

BioAge Labs Inc

Last Close
5.87
Oct 30 • 3:59 PM ET Dollar change-0.07 Percentage change(-1.18%)
Aftermarket Close
5.87
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Drug Manufacturers - Specialty & Generic USA Micro NASD
Peers: ALT GPCR EYPT KOD NAMS MLYS OCUL CRBP VKTX NVO
 | Held by: VTI IWM VXF XPH IWN IBB DFAS VTWO FESM SCHA
Scroll to Statements
Index
RUT
Market Cap
269.41M
Enterprise Value
-46.51M
Income
-94.46M
Sales
10.36M
Book/sh
8.19
Cash/sh
6.95
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
62
IPO
Sep 26, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
26.00
P/B
0.72
P/C
0.85
P/FCF
-
EV/EBITDA
-
EV/Sales
-4.49
Quick Ratio
17.19
Current Ratio
17.19
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-2.39
EPS next Y
-2.26
EPS next Q
-0.63
EPS this Y
-9.97%
EPS next Y
8.27%
EPS next 5Y
-3.84%
EPS past 3/5Y
-24.49% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-6.76%
Sales Y/Y TTM
168.06%
EPS Q/Q
3.24%
Sales Q/Q
1.62%
Earnings
Aug 05 AMC
EPS/Sales Surpr.
4.50% 63.65%
Insider Own
31.58%
Insider Trans
-0.43%
Inst Own
61.59%
Inst Trans
11.55%
ROA
-26.27%
ROE
-28.21%
ROIC
-25.05%
Gross Margin
97.58%
Oper. Margin
-1026.28%
Profit Margin
-912.25%
SMA20
3.45%
SMA50
-20.60%
SMA200
-62.89%
Trades
Shs Outstand
45.78M
Shs Float
31.40M
Short Float
10.93%
Short Ratio
3.57
Short Interest
3.43M
52W High
25.95 -77.38%
52W Low
4.81 22.04%
Volatility
8.75% 7.27%
ATR (14)
0.45
RSI (14)
43.38
Beta
1.10
Rel Volume
0.83
Avg Volume
959.97K
Volume
801,369
Perf Week
15.10%
Perf Month
-13.80%
Perf Quarter
-45.55%
Perf Half Y
-65.04%
Perf YTD
-55.63%
Perf Year
-24.06%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Recom
1.60
Target Price
32.56
Prev Close
5.94
Price
5.87
Change %
-1.18%
Consensus
Buy
Avg. Price Target
$32.56
Implied Upside
+454.7%
Analysts10incl. previous ratings
Rating Distribution7 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 12, 2026Initiated
UBS logoUUBS
Neutral$8+36.3%
May 27, 2026Initiated
RRoth Capital
Buy$36+513.3%
May 13, 2026Initiated
BBTIG Research
Buy$40+581.4%
Mar 27, 2026Initiated
NNeedham
Buy$50+751.8%
Feb 25, 2026Initiated
OPY logoOOppenheimer
Outperform$60+922.1%
Feb 18, 2026Upgrade
JEF logoJJefferies
Hold → Buy$62+956.2%
Jan 27, 2026Initiated
PPiper Sandler
Overweight$73+1,143.6%
Dec 05, 2025Upgrade
MS logoMMorgan Stanley
Underweight → Equal-Weight$12+104.4%
Oct 22, 2025Upgrade
C logoCCitigroup
Neutral → Buy$10+70.4%
Feb 28, 2025Initiated
WWilliam Blair
Mkt Perform
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barton ShanePrincipal Accounting OfficerJun 29 '26Option Exercise6.6139,718262,54242,350Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 30 '26Option Exercise6.5320,216132,01720,216Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 29 '26Sale25.2142,3501,067,5760Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 30 '26Sale25.1920,216509,1760Jul 01 04:27 PM
Barton ShaneOfficerJun 30 '26Proposed Sale25.1920,216509,177Jun 30 04:21 PM
Barton ShaneOfficerJun 29 '26Proposed Sale25.2142,3501,067,578Jun 29 04:35 PM
GOLDSTEIN DOV A MDChief Financial OfficerApr 23 '26Option Exercise4.383,54215,51436,575Apr 24 04:19 PM
RUBIN PAUL DChief Medical OfficerApr 01 '26Option Exercise5.058,82044,5728,820Apr 03 04:07 PM
RUBIN PAUL DChief Medical OfficerApr 01 '26Sale17.818,820157,0840Apr 03 04:07 PM
RUBIN PAUL DOfficerApr 01 '26Proposed Sale17.818,820157,084Apr 01 10:53 AM
RUBIN PAUL DChief Medical OfficerMar 02 '26Option Exercise4.777,43335,4707,433Mar 03 04:46 PM
RUBIN PAUL DChief Medical OfficerMar 02 '26Sale20.307,433150,8900Mar 03 04:46 PM
GOLDSTEIN DOV A MDChief Financial OfficerMar 01 '26Option Exercise4.383,54215,51433,033Mar 03 04:44 PM
RUBIN PAUL DOfficerMar 02 '26Proposed Sale20.037,433148,883Mar 02 10:17 AM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Option Exercise4.777,43335,4707,433Feb 03 04:26 PM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Sale18.757,433139,3690Feb 03 04:26 PM
GOLDSTEIN DOV A MDChief Financial OfficerFeb 01 '26Option Exercise4.383,54115,51029,491Feb 03 04:23 PM
RUBIN PAUL DOfficerFeb 02 '26Proposed Sale18.757,433139,369Feb 02 09:43 AM
GOLDSTEIN DOV A MDChief Financial OfficerJan 16 '26Option Exercise4.383,54215,51425,950Jan 21 04:20 PM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Option Exercise8.3927,000226,53049,408Jan 15 04:22 PM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Sale19.7027,000531,82822,408Jan 15 04:22 PM
Fortney KristenChief Executive OfficerJan 13 '26Sale18.12233,1074,223,036976,949Jan 15 04:20 PM
Fortney Kristen10% OwnerJan 13 '26Proposed Sale18.00233,1074,195,926Jan 13 04:36 PM
GOLDSTEIN DOV A MDOfficerJan 13 '26Proposed Sale19.7027,000531,828Jan 13 04:16 PM
RUBIN PAUL DChief Medical OfficerJan 02 '26Option Exercise4.777,43335,4707,433Jan 06 04:24 PM
RUBIN PAUL DChief Medical OfficerJan 02 '26Sale12.857,43395,4900Jan 06 04:24 PM
RUBIN PAUL DOfficerJan 02 '26Proposed Sale13.417,43399,677Jan 02 12:56 PM
RUBIN PAUL DChief Medical OfficerDec 09 '25Option Exercise6.5718,000118,26018,000Dec 11 04:21 PM
RUBIN PAUL DChief Medical OfficerDec 09 '25Sale12.0018,000216,0000Dec 11 04:21 PM
RUBIN PAUL DOfficerDec 09 '25Proposed Sale12.0018,000216,000Dec 09 11:23 AM
RUBIN PAUL DChief Medical OfficerDec 04 '25Option Exercise4.1168,897283,16768,897Dec 05 06:20 PM
RUBIN PAUL DChief Medical OfficerDec 04 '25Sale10.1968,897701,9090Dec 05 06:20 PM
RUBIN PAUL DOfficerDec 04 '25Proposed Sale10.1968,897701,912Dec 04 04:30 PM
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
Co-FounderDr. Kristen Fortney Ph.D.
Co-FounderDr. Eric Morgen M.D.
Chief Medical Officer & Executive VP of ResearchDr. Paul D. Rubin M.D.
M.D.Dr. Dov A. Goldstein M.B.A.
Senior Vice President of Finance & AccountingMr. Shane Barton CPA
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)